Mobile Menu

  • AboutUs_Normal-24 The EyeCRO Approach
    • About Us
    • Careers
    • Location
    • Partners
  • MiDrops MiDROPS™
  • InVivo Models
    • Allergic Conjunctivitis
    • Corneal Sensitivity
    • Corneal Wound Healing
    • Diabetic Keratopathy
    • Dry Eye Disease
    • Endotoxin induced Uveitis
    • Experimental Autoimmune Uveitis
    • Geographic Atrophy
    • Inherited Retinal Degenerations
    • Ischemia Reperfusion Injury
    • Laser-induced Choroidal Neovascularization
    • Light Damaged
    • Optic Nerve Crush
    • Oxygen Induced Retinopathy
    • Retinal Detachment
    • Retinal Vein Occlusion
    • Rotenone-induced Optic Neuropathy
    • STZ-induced Diabetic Retinopathy
    • VEGF-induced permeability
  • InVitro Capabilities
    • Biochemistry
    • Bioanalytical Detection
    • GLP Toxicology and PK Studies
    • Histology
    • Ophthalmic Imaging and Physiology
  • News News
  • ContactUs Contact Us
  • Menu
  • Skip to primary navigation
  • Skip to main content

EyeCRO Logo

  • AboutUs_Normal-24 The EyeCRO Approach
    • About Us
    • Careers
    • Location
    • Partners
  • MiDrops MiDROPS™
  • InVivo Models
    • Allergic Conjunctivitis
    • Corneal Sensitivity
    • Corneal Wound Healing
    • Diabetic Keratopathy
    • Dry Eye Disease
    • Endotoxin induced Uveitis
    • Experimental Autoimmune Uveitis
    • Geographic Atrophy
    • Inherited Retinal Degenerations
    • Ischemia Reperfusion Injury
    • Laser-induced Choroidal Neovascularization
    • Light Damaged
    • Optic Nerve Crush
    • Oxygen Induced Retinopathy
    • Retinal Detachment
    • Retinal Vein Occlusion
    • Rotenone-induced Optic Neuropathy
    • STZ-induced Diabetic Retinopathy
    • VEGF-induced permeability
  • InVitro Capabilities
    • Bioanalytical Detection
    • Biochemistry
    • GLP Toxicology and PK Studies
    • Histology
    • Ophthalmic Imaging and Physiology
  • News News
  • ContactUs Contact Us

Preclinical Ophthalmic Contract Research

EyeCRO specializes in preclinical ophthalmic studies to examine the efficacy of novel test agents and therapeutic modalities.  Our models are well established and optimized to facilitate generation of reproducible datasets with meaningful endpoints.
With over two decades of experience in vision research, our expert scientists can help you select the right model and experimental design to achieve your research and development goals.  We also offer Toxicology/PK studies, and eyedrop formulations in MiDROPS™.

  • goggles
  • scope
  • team1
  • lcms
  • slide
  • erg
  • cnv
  • histo
  • okt
  • midrops-vials
  • ded
  • injection
  • ideas
  • chem2
  • micron

The Global Leader in Preclinical Ophthalmic Research

Microemulsion Drug Ocular Penetration System MiDROPS™

MiDROPS™ was developed to allow for eyedrop formulation of small molecules that are lipophilic.  This technology represents a fundamentally new approach for ophthalmic drug delivery using microemulsions which are thermodynamically stable.  These self-assembling vehicles can formulate high concentrations of drugs and deliver them in abundant quantities to both the anterior segment and posterior segment.  Our broad patents are issued in the US and Worldwide and protect millions of different formulations covered in our library.

midrops vials

Click here to learn more about this innovative platform technology

Models

Allergic Conjunctivitis

Corneal Sensitivity

Corneal Wound Healing

Diabetic Keratopathy

Dry Eye Disease

Endotoxin induced Uveitis

Experimental Autoimmune Uveitis

Geographic Atrophy

Inherited Retinal Degenerations

Ischemia Reperfusion Injury

Laser-induced Choroidal Neovascularization

Light Damaged

Optic Nerve Crush

Oxygen Induced Retinopathy

Retinal Detachment

Retinal Vein Occlusion

Rotenone-induced Optic Neuropathy

STZ-induced Diabetic Retinopathy

VEGF-induced permeability

Capabilities

Bioanalytical Detection

Biochemistry

GLP Toxicology and PK Studies

Histology

Ophthalmic Imaging and Physiology

News & Events

InMed Licenses MiDROPS® Delivery Technology from EyeCRO for the Delivery of Therapeutic Cannabinoids

Inmed Pharmaceuticals Inc. (NASD: INM) has secured a worldwide license to formulate any cannabinoid molecule using MiDROPS® for ophthalmic instillation. Click here to read the full press release.

InMed Licenses MiDROPS® Delivery Technology from EyeCRO for the Delivery of Therapeutic CannabinoidsRead More

EyeCRO scientists contribute to study published in Nature

“Researchers have discovered a technique for directly reprogramming skin cells into light-sensing rod photoreceptors used for vision. The lab-made rods enabled blind mice to detect light after the cells were transplanted into the animals’ eyes. The…

EyeCRO scientists contribute to study published in NatureRead More

Is Treat-and-Extend Truly Effective for Diabetic Macular Edema?

“Anti-vascular endothelial growth factor (anti-VEGF) medications have a proven track record in treating diabetic macular edema (DME). However, researchers continue to investigate whether these medications can be made more efficient and cost-effective.” “Both the RETAIN[1] and REACT[2] studies showed that…

Is Treat-and-Extend Truly Effective for Diabetic Macular Edema?Read More

New Age-Related Macular Degeneration Common in Untreated Fellow Eyes

“NEW YORK (Reuters Health) – New age-related macular degeneration (AMD) develops in about a quarter of fellow eyes to those treated for neovascular AMD with intravitreal anti-VEGF agents, according to a post hoc analysis of the…

New Age-Related Macular Degeneration Common in Untreated Fellow EyesRead More

Double-Barreled Biologic for Diabetic Retinopathy Emerging

CHICAGO — Investigators searching for new ways to manage diabetic macular edema are targeting pathways beyond vascular endothelial growth factor (VEGF). Phase 2 results from the BOULEVARD trial (NCT02699450), which is comparing faricimab, the first biologic to target both…

Double-Barreled Biologic for Diabetic Retinopathy EmergingRead More

FLUID Study Rethinks Treat-and-Extend Protocols in Neovascular AMD

“For patients with neovascular age-related macular degeneration (nAMD), a major cause of visual impairment worldwide,[1] the advent of anti–vascular endothelial growth factor (VEGF) intravitreal injections has been an undeniable breakthrough.  Anti-VEGF therapy allows for greater control of…

FLUID Study Rethinks Treat-and-Extend Protocols in Neovascular AMDRead More

View All Posts

EyeCRO on Twitter

Retweet on TwitterEyeCRO Retweeted
DrugDeliveryNowDrug Delivery News@DrugDeliveryNow·
March 1, 2021

RNA-based #Therapeutic developer @DTxPharma announced today that it completed a $100 million Series B #Financing round. RA Capital Management led the financing round with participation from multiple new #Investors.

https://www.drugdeliverybusiness.com/dtx-pharma-completes-100m-series-b/

#ClinicalDevelopment #Tech #BioTech

Reply on Twitter 1366478605002375168Retweet on Twitter 13664786050023751681Like on Twitter 13664786050023751681Twitter 1366478605002375168
EyeCROEyeCRO@EyeCRO·
February 23, 2021

Novel AAV capsids for intravitreal gene therapy of photoreceptor disorders - PubMed https://pubmed.ncbi.nlm.nih.gov/33616280/

Reply on Twitter 1364180885503901701Retweet on Twitter 1364180885503901701Like on Twitter 1364180885503901701Twitter 1364180885503901701
Retweet on TwitterEyeCRO Retweeted
NASAPersevereNASA's Perseverance Mars Rover@NASAPersevere·
February 22, 2021

Your front-row seat to my Mars landing is here. Watch how we did it.

#CountdownToMars

Reply on Twitter 1363929492138254340Retweet on Twitter 136392949213825434068445Like on Twitter 1363929492138254340217262Twitter 1363929492138254340
Load More...

Contact Us

pen and post it

EyeCRO – Headquarters

5301 N. Beverly Drive
Oklahoma City, OK 73105
(405) 604-8954

EyeCRO – Ann Arbor

173 Parkland Plaza, Suite C
Ann Arbor, MI 48103
(734) 997-5455

info@eyecro.com

Request more information

  • This field is for validation purposes and should be left unchanged.

© 2021 · EyeCRO · All Rights Reserved.